Literature DB >> 29419430

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Pankaj Yadav1, Maximilian Merz2, Elias K Mai2, Asta Försti3,4, Anna Jauch5, Hartmut Goldschmidt2,6, Kari Hemminki3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29419430      PMCID： PMC5865437          DOI： 10.3324/haematol.2017.184226

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

Authors:  Kai Neben; Henk M Lokhorst; Anna Jauch; Uta Bertsch; Thomas Hielscher; Bronno van der Holt; Hans Salwender; Igor W Blau; Katja Weisel; Michael Pfreundschuh; Christof Scheid; Ulrich Dührsen; Walter Lindemann; Ingo G H Schmidt-Wolf; Norma Peter; Christian Teschendorf; Hans Martin; Mathias Haenel; Hans G Derigs; Marc S Raab; Anthony D Ho; Helgi van de Velde; Dirk Hose; Pieter Sonneveld; Hartmut Goldschmidt
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Authors:  Maximilian Merz; Hans Salwender; Mathias Haenel; Elias K Mai; Uta Bertsch; Christina Kunz; Thomas Hielscher; Igor W Blau; Christof Scheid; Dirk Hose; Anja Seckinger; Anna Jauch; Jens Hillengass; Marc S Raab; Baerbel Schurich; Markus Munder; Ingo G H Schmidt-Wolf; Christian Gerecke; Hans-Walter Lindemann; Matthias Zeis; Katja Weisel; Jan Duerig; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

Review 3.  Genomic complexity of multiple myeloma and its clinical implications.

Authors:  Salomon Manier; Karma Z Salem; Jihye Park; Dan A Landau; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2016-08-17       Impact factor: 66.675

4.  Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Authors:  Dirk Hose; Thierry Rème; Thomas Hielscher; Jérôme Moreaux; Tobias Messner; Anja Seckinger; Axel Benner; John D Shaughnessy; Bart Barlogie; Yiming Zhou; Jens Hillengass; Uta Bertsch; Kai Neben; Thomas Möhler; Jean François Rossi; Anna Jauch; Bernard Klein; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

5.  Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.

Authors:  Tilmann Bochtler; Ute Hegenbart; Christiane Heiss; Axel Benner; Friedrich Cremer; Martin Volkmann; Jochen Ludwig; Jolanta B Perz; Anthony D Ho; Hartmut Goldschmidt; Stefan O Schonland
Journal:  Haematologica       Date:  2008-02-20       Impact factor: 9.941

6.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authors:  Antonio Palumbo; Hervé Avet-Loiseau; Stefania Oliva; Henk M Lokhorst; Hartmut Goldschmidt; Laura Rosinol; Paul Richardson; Simona Caltagirone; Juan José Lahuerta; Thierry Facon; Sara Bringhen; Francesca Gay; Michel Attal; Roberto Passera; Andrew Spencer; Massimo Offidani; Shaji Kumar; Pellegrino Musto; Sagar Lonial; Maria T Petrucci; Robert Z Orlowski; Elena Zamagni; Gareth Morgan; Meletios A Dimopoulos; Brian G M Durie; Kenneth C Anderson; Pieter Sonneveld; Jésus San Miguel; Michele Cavo; S Vincent Rajkumar; Philippe Moreau
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

7.  Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

Authors:  A Bradwell; S Harding; N Fourrier; C Mathiot; M Attal; P Moreau; J-L Harousseau; H Avet-Loiseau
Journal:  Leukemia       Date:  2012-06-13       Impact factor: 11.528

8.  Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

Authors:  Verónica González-Calle; Seila Cerdá; Jorge Labrador; Eduardo Sobejano; Beatriz González-Mena; Carmen Aguilera; Enrique María Ocio; María Belén Vidriales; Noemí Puig; Norma Carmen Gutiérrez; Ramón García-Sanz; José María Alonso; Rosa López; Carlos Aguilar; Alfonso García de Coca; Roberto Hernández; José Mariano Hernández; Fernando Escalante; María-Victoria Mateos
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

9.  Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.

Authors:  M Michallet; C Chapuis-Cellier; T Dejoie; C Lombard; H Caillon; M Sobh; P Moreau; M Attal; H Avet-Loiseau
Journal:  Leukemia       Date:  2017-06-30       Impact factor: 11.528

10.  Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.

Authors:  Heinz Ludwig; Dejan Milosavljevic; Oscar Berlanga; Niklas Zojer; Wolfgang Hübl; Veronique Fritz; Stephen Harding
Journal:  Am J Hematol       Date:  2016-03       Impact factor: 10.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.